Biologics

A Cincinnati pain management physician led the first prospective controlled trial in the world on treating chronic back pain with stem cells, with about 70 percent of participants seeing positive results.

Royal Biologics received FDA approval for its MAXX-BMC bone marrow aspirate concentration system.

Although further research is needed to determine the safety and efficacy of regenerative procedures in the spine, the potential of many of these therapies — such as stem cells, platelet-rich plasma and bone marrow aspirate — is considerable.

From patent updates to grants, here are five developments in orthopedic biologics over the last 30 days:

Ortho Regenerative Technologies received a $500,000 grant from Axelys to develop its Ortho-M meniscus repair product.

Several orthopedic regenerative products have been released or FDA approved in 2022.

Bonesupport's Cerament G, an injectable combination antibiotic bone graft substitute, earned FDA market authorization.

Regenerative medicine in spine and orthopedics is gaining momentum, and many surgeons expect further development and research for the field in the near future.

Kuros Biosciences launched the MagnetOs Easypack Putty in the U.S.

Ortho Regenerative Technologies received a patent related to its Ortho-R soft tissue repair platform.